The accounts we keep within reach
The links lead to the papers, reviews and labels discussed in these essays. Each has a different job here.
Semaglutide beyond a single headline
The adult weight trial tested semaglutide in adults without diabetes. Obesity was one entry route; overweight paired with a related condition was another. It is the source for the weight finding.
The heart-outcomes study involved people who already had cardiovascular disease. They also had excess weight but didn’t have diabetes. Keeping that setting visible helps explain who the finding concerns.
The kidney study followed people whose type 2 diabetes occurred alongside chronic kidney disease. It answers a different health question from the weight trial.
The semaglutide safety review gathers findings on side effects and cautions. It’s a review, rather than a new trial with its own participants.
Comparisons and experimental work
The direct obesity comparison tested tirzepatide against semaglutide. Tirzepatide’s maker funded it, and participants knew their assigned treatment. Those details belong beside the result.
The diabetes comparison studied the two in adults with type 2 diabetes. Its population and treatments matter when deciding what can be compared.
The early retatrutide obesity trial used placebo, a dummy treatment, rather than either of those medicines. It supplies the weight, digestive and heart-rate findings discussed here.
The retatrutide receptor paper examines interactions with three signal receivers. It helps explain the mechanism; it isn’t a treatment outcome in people.
Scans, follow-up and animal experiments
The tesamorelin scan study measured deep abdominal and liver fat in adults with HIV. The longer follow-up records fat returning after treatment stopped.
The NIH tesamorelin account adds clinical context. We use it alongside the studies, keeping the particular approved setting in view.
The BPC-157 stomach-ulcer experiment was in rats. The blood-vessel paper explores a possible mechanism. Neither establishes human injury healing.
The musculoskeletal review explains the small human record for BPC-157 and its limits. Reviews can help you see what is missing as well as what has been tried.
Labels and FDA context
The Wegovy (semaglutide) label, Zepbound (tirzepatide) label and Egrifta WR (tesamorelin) label describe approved products and their warnings. A label doesn’t transfer to every preparation using the ingredient’s name.
FDA’s safety page includes BPC-157 under nominated-but-withdrawn substances, and keeps the safety cautions beside the entry. Its current-content date is April 22, 2026; it supplies no date for the withdrawal. Withdrawal gives no clearance or permission to compound.
We link the relevant source beside each finding in the essays. This list gives you another way in when you want to read the original for yourself.